➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
McKesson
Merck
Baxter
Medtronic
AstraZeneca

Last Updated: October 23, 2021

DrugPatentWatch Database Preview

CUBICIN Drug Patent Profile


Email this page to a colleague

« Back to Dashboard

When do Cubicin patents expire, and when can generic versions of Cubicin launch?

Cubicin is a drug marketed by Cubist Pharms Llc and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has three patent family members in three countries.

The generic ingredient in CUBICIN is daptomycin. There are ten drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the daptomycin profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Cubicin

A generic version of CUBICIN was approved as daptomycin by HOSPIRA INC on September 12th, 2014.

  Try it Free

Drug patent expirations by year for CUBICIN
Drug Prices for CUBICIN

See drug prices for CUBICIN

Recent Clinical Trials for CUBICIN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
M.D. Anderson Cancer CenterPhase 2
Vancouver Island Health AuthorityPhase 4
Poitiers University HospitalPhase 3

See all CUBICIN clinical trials

Pharmacology for CUBICIN
Paragraph IV (Patent) Challenges for CUBICIN
Tradename Dosage Ingredient NDA Submissiondate
CUBICIN POWDER;INTRAVENOUS daptomycin 021572 2008-11-19
CUBICIN RF POWDER;INTRAVENOUS daptomycin 021572 2008-11-19

US Patents and Regulatory Information for CUBICIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Cubist Pharms Llc CUBICIN daptomycin POWDER;INTRAVENOUS 021572-001 Sep 12, 2003 DISCN No No ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Cubist Pharms Llc CUBICIN daptomycin POWDER;INTRAVENOUS 021572-002 Sep 12, 2003 AP RX Yes Yes ⤷  Try it Free ⤷  Try it Free ⤷  Try it Free
Cubist Pharms Llc CUBICIN RF daptomycin POWDER;INTRAVENOUS 021572-003 Jul 6, 2016 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for CUBICIN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Cubist Pharms Llc CUBICIN daptomycin POWDER;INTRAVENOUS 021572-001 Sep 12, 2003 ⤷  Try it Free ⤷  Try it Free
Cubist Pharms Llc CUBICIN daptomycin POWDER;INTRAVENOUS 021572-001 Sep 12, 2003 ⤷  Try it Free ⤷  Try it Free
Cubist Pharms Llc CUBICIN daptomycin POWDER;INTRAVENOUS 021572-002 Sep 12, 2003 ⤷  Try it Free ⤷  Try it Free
Cubist Pharms Llc CUBICIN daptomycin POWDER;INTRAVENOUS 021572-002 Sep 12, 2003 ⤷  Try it Free ⤷  Try it Free
Cubist Pharms Llc CUBICIN daptomycin POWDER;INTRAVENOUS 021572-001 Sep 12, 2003 ⤷  Try it Free ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for CUBICIN

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1115417 SZ 22/2006 Austria ⤷  Try it Free PRODUCT NAME: DAPTOMYCIN
1115417 300232 Netherlands ⤷  Try it Free DETAILS ASSIGNMENT: VERANDERING VAN EIGENAAR(S), VERANDERING VAN DE JURIDISCHE ENTITEIT
1115417 22/2006 Austria ⤷  Try it Free PRODUCT NAME: DAPTOMYCIN; REGISTRATION NO/DATE: EU/1/05/328/001 UND 002 20060119
1115417 SPC 018/2006 Ireland ⤷  Try it Free SPC 018/2006: 20070523, EXPIRES: 20210118
1115417 06C0022 France ⤷  Try it Free PRODUCT NAME: DAPTOMYCINE; REGISTRATION NO/DATE: EU/1/05/328/001-002 20060119
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
McKesson
Merck
Baxter
Medtronic
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.